{"id":6924,"date":"2019-06-28T15:54:12","date_gmt":"2019-06-28T15:54:12","guid":{"rendered":"https:\/\/oncopeptides.com\/investors\/aktien\/nyemissioner\/nyemission-juni-2019\/"},"modified":"2026-03-19T15:49:35","modified_gmt":"2026-03-19T15:49:35","slug":"nyemission-juni-2019","status":"publish","type":"investors","link":"https:\/\/oncopeptides.com\/sv\/investerare\/aktien\/nyemissioner\/nyemission-juni-2019\/","title":{"rendered":"Nyemission juni 2019"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"6924\" class=\"elementor elementor-6924 elementor-6816\" data-elementor-post-type=\"investors\">\n\t\t\t\t<style>\n                .elementor-element-436c271{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-436c271 e-flex e-con-boxed e-con e-parent\" data-id=\"436c271\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<style>\n                .elementor-element-10430e8{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-10430e8 e-con-full haus-2-1 e-flex e-con e-child\" data-id=\"10430e8\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e8bf6c4 elementor-widget elementor-widget-heading\" data-id=\"e8bf6c4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Nyemission<br><span style=\"color: var(--color-orange)\">juni 2019<\/span><\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9698e48 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"9698e48\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-2383dcd{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-2383dcd e-con-full e-flex e-con e-child\" data-id=\"2383dcd\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-db322b6 elementor-widget elementor-widget-text-editor\" data-id=\"db322b6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Oncopeptides har genomf\u00f6rt en riktad nyemission om cirka 727 MSEK (78 MUSD)<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3146d4b elementor-widget elementor-widget-text-editor\" data-id=\"3146d4b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>28 juni 2019 \u2013 Regulatoriskt pressmeddelande<\/p><p>Oncopeptides AB (publ) meddelar att bolaget framg\u00e5ngsrikt har genomf\u00f6rt en riktad nyemission om cirka 727 MSEK (78 MUSD).<\/p><p>Oncopeptides styrelse har, med st\u00f6d av emissionsbemyndigandet som beslutades av \u00e5rsst\u00e4mman den 21 maj 2019 och i enlighet med vad som angavs i bolagets pressmeddelande den 27 juni 2019, beslutat om en riktad nyemission av 5 015 000 nya aktier (\u201dDe Nya Aktierna\u201d) till en teckningskurs om 145 SEK per aktie (\u201dEmissionen\u201d), vilket inneb\u00e4r att bolaget tillf\u00f6rs en bruttolikvid om cirka 727 MSEK (78 MUSD).<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9ac2138 elementor-widget elementor-widget-button\" data-id=\"9ac2138\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-ab-oncopeptides-har-genomfort-en-riktad-nyemission-om-cirka-727-miljoner-kronor\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3efeb63 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"3efeb63\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-2cca76e{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-2cca76e e-con-full e-flex e-con e-child\" data-id=\"2cca76e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5ad9f33 elementor-widget elementor-widget-text-editor\" data-id=\"5ad9f33\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Oncopeptides avser att genomf\u00f6ra en riktad nyemission<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1b4015d elementor-widget elementor-widget-text-editor\" data-id=\"1b4015d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>27 juni 2019 \u2013 Regulatoriskt pressmeddelande<\/p><p>Oncopeptides AB (publ) meddelar sin avsikt att genomf\u00f6ra en riktad nyemission till institutionella investerare (\u201dEmissionen\u201d). Bolaget har anlitat Carnegie Investment Bank AB (publ), Cowen and Company LLC, DNB Markets, en del av DNB Bank ASA, Jefferies International Limited och Kempen &amp; Co N.V. som Joint Bookrunners (\u201dJoint Bookrunners\u201d) i samband med Emissionen. Bookbuilding inleds omedelbart efter detta meddelande.    <\/p><p class=\"mfn-wp-retain\">Teckningskursen och det totala antalet nya aktier i Emissionen (\u201dEmissionsaktierna\u201d) kommer att fastst\u00e4llas genom ett accelererat bookbuild-f\u00f6rfarande (\u201dBookbuilding\u201d). Avsikten \u00e4r att antalet nyemitterade aktier ska uppg\u00e5 till cirka 10 procent av det totala antalet aktier i bolaget. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-eed8365 elementor-widget elementor-widget-button\" data-id=\"eed8365\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-ab-oncopeptides-avser-att-genomfora-en-riktad-nyemission-3\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"featured_media":0,"parent":5698,"menu_order":0,"template":"","meta":{"_acf_changed":false},"protected-content":[341],"class_list":["post-6924","investors","type-investors","status-publish","hentry","protected-content-show-disclaimer"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/6924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/investors"}],"version-history":[{"count":1,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/6924\/revisions"}],"predecessor-version":[{"id":6925,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/6924\/revisions\/6925"}],"up":[{"embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/5698"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=6924"}],"wp:term":[{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/protected-content?post=6924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}